176 related articles for article (PubMed ID: 28808592)
1. A Case of Fulminant Meningococcemia: It Is All in the Complement.
Hawkins KL; Hoffman M; Okuyama S; Rowan SE
Case Rep Infect Dis; 2017; 2017():6093695. PubMed ID: 28808592
[TBL] [Abstract][Full Text] [Related]
2. Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab.
Alashkar F; Vance C; Herich-Terhürne D; Preising N; Dührsen U; Röth A
Ann Hematol; 2017 Apr; 96(4):589-596. PubMed ID: 28124080
[TBL] [Abstract][Full Text] [Related]
3. Non-capsulated
Galli N; Pettine L; Panigada M; Daprai L; Suriano G; Grancini A; Barcellini W; Fattizzo B
Front Immunol; 2023; 14():1269325. PubMed ID: 37854608
[TBL] [Abstract][Full Text] [Related]
4. Fatal Nongroupable Neisseria meningitidis Disease in Vaccinated Patient Receiving Eculizumab.
Nolfi-Donegan D; Konar M; Vianzon V; MacNeil J; Cooper J; Lurie P; Sedivy J; Wang X; Granoff DM; McNamara L
Emerg Infect Dis; 2018 Aug; 24(8):1561-4. PubMed ID: 30015608
[TBL] [Abstract][Full Text] [Related]
5. Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients.
Langereis JD; van den Broek B; Franssen S; Joosten I; Blijlevens NMA; de Jonge MI; Langemeijer S
Blood Adv; 2020 Aug; 4(15):3615-3620. PubMed ID: 32766853
[TBL] [Abstract][Full Text] [Related]
6. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
Front Immunol; 2019; 10():1157. PubMed ID: 31258525
[TBL] [Abstract][Full Text] [Related]
7. A rare case of septic shock due to Neisseria meningitidis serogroup B infection despite prior vaccination in a young adult with paroxysmal nocturnal haemoglobinuria receiving eculizumab.
Reher D; Fuhrmann V; Kluge S; Nierhaus A
Vaccine; 2018 May; 36(19):2507-2509. PubMed ID: 29631884
[TBL] [Abstract][Full Text] [Related]
8. [Paroxysmal nocturnal hemoglobinuria and thrombosis in the era of eculizumab].
Nishimura JI
Rinsho Ketsueki; 2018; 59(8):1042-1047. PubMed ID: 30185704
[TBL] [Abstract][Full Text] [Related]
9. Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settings.
Kelly RJ; Nishimori H; Horneff R; Hillmen P; Al-Adhami M; Lallier S; Gerber GF
Res Pract Thromb Haemost; 2024 May; 8(4):102416. PubMed ID: 38812989
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.
Kanakura Y; Ohyashiki K; Shichishima T; Okamoto S; Ando K; Ninomiya H; Kawaguchi T; Nakao S; Nakakuma H; Nishimura J; Kinoshita T; Bedrosian CL; Valentine ME; Khursigara G; Ozawa K; Omine M
Int J Hematol; 2011 Jan; 93(1):36-46. PubMed ID: 21222185
[TBL] [Abstract][Full Text] [Related]
11. Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria.
Keating GM; Lyseng-Williamson KA; McKeage K
BioDrugs; 2012 Apr; 26(2):125-30. PubMed ID: 22350448
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab.
Cooper JP; Farah RJ; Stevenson PA; Gooley TA; Storb R; Scott BL
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1331-1339. PubMed ID: 30711779
[TBL] [Abstract][Full Text] [Related]
13. C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications.
Notaro R; Sica M
Semin Hematol; 2018 Jul; 55(3):130-135. PubMed ID: 30032749
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil activation and nucleosomes as markers of systemic inflammation in paroxysmal nocturnal hemoglobinuria: effects of eculizumab.
van Bijnen ST; Wouters D; van Mierlo GJ; Muus P; Zeerleder S
J Thromb Haemost; 2015 Nov; 13(11):2004-11. PubMed ID: 26333021
[TBL] [Abstract][Full Text] [Related]
15. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
Risitano AM; Perna F; Selleri C
Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
[TBL] [Abstract][Full Text] [Related]
16. [Management of paroxysmal nocturnal hemoglobinuria: an update].
Kawaguchi T
Rinsho Ketsueki; 2018; 59(6):703-710. PubMed ID: 29973448
[TBL] [Abstract][Full Text] [Related]
17. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
Risitano AM
Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
[TBL] [Abstract][Full Text] [Related]
18. Eculizumab: A novel therapy for paroxysmal nocturnal hemoglobinuria.
Zareba KM
Drugs Today (Barc); 2007 Aug; 43(8):539-46. PubMed ID: 17925885
[TBL] [Abstract][Full Text] [Related]
19. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Hall C; Marsh JC; Elebute M; Bombara MP; Petro BE; Cullen MJ; Richards SJ; Rollins SA; Mojcik CF; Rother RP
N Engl J Med; 2004 Feb; 350(6):552-9. PubMed ID: 14762182
[TBL] [Abstract][Full Text] [Related]
20. A patient with paroxysmal nocturnal hemoglobinuria being treated with eculizumab who underwent laparoscopic cholecystectomy: report of a case.
Moriyama M; Nagata T; Yoshioka I; Hashimoto I; Matsui K; Okumura T; Tsukada K
Surg Case Rep; 2015; 1(1):57. PubMed ID: 26366354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
